Guardant Health AMEA and GC Genome announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in South Korea.
Home » Guardant Health AMEA and GC Genome announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in South Korea.

GH AMEA on Social MediaGuardant Health AMEA and GC Genome announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in South Korea.
Guardant Health AMEA and GC Genome announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360<sup data-src=
Guardant Health AMEA and GC Genome announced today a collaboration to market Guardant Health’s liquid biopsy, Guardant360®, in South Korea.
LinkedIn

“Guardant Health AMEA is pleased to launch the Guardant360® assay in South Korea to help cancer patients get the right cancer treatment with our breakthrough liquid biopsy. Guardant360® also offers physicians and patients rapid access to results often times faster than traditional tissue-based testing options. In as little as seven days upon receipt in our lab we can provide physicians and patients with the results they need to guide appropriate treatment,” said Mr. Simranjit Singh, Chief Executive Officer of Guardant Health AMEA. Professor Byoung Chul Cho from Yonsei Severance Hospital also shared his experience with Guardant360® in clinical practice.

Open chat
Message us